The psychedelic drug industry continues to advance by leaps-and-bounds. But psychedelic drug stocks are well off recent highs. The sale is on!
Psychedelics
COMPASS Pathways plc announces financial results and business highlights for fourth quarter and year-end 2020
Compass expecting to report data from its Phase IIb study by the end of 2021. Cash on hand decreases to $190.3 million, from $196.5 million the previous quarter.
Red Light Holland's Psychedelic Virtual Reality Experience, Wisdom, Narrated by Global Comedy Superstar Russell Peters, Accepted to Steam, the Largest Digital Distribution Platform for PC Gaming
Red Light Holland gets its VR "experience" hosted on the largest PC gaming platform.
MindMed Announces C$19.5 Million Bought Deal Private Placement Offering
MindMed raises CAD$19.5 million selling units at CAD$3.25.
Previous antidepressant use may blunt the effectiveness of MDMA-assisted psychotherapy for PTSD
New research suggests that MDMA-assisted therapy for the treatment of posttraumatic stress disorder (PTSD) is less effective among those who have recently used selective serotonin reuptake inhibitors (SSRIs), a common psychiatric medication.
The Race to Patent Psychedelics Is Just Getting Started
The author and podcast host Tim Ferriss has done his share of heavy lifting when it comes to supporting and promoting research on psychedelic drugs.
Local Activists In Washington State Push For Psilocybin Decriminalization
Voters in Spokane, Washington could make the city one of the latest to decriminalize psilocybin mushrooms under a proposed ordinance that was recently filed by local activists.
MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
This potential treatment opportunity was confirmed by the company's bioinformatics platform, PsyCollage
MagicMed Industries Announces Collaboration with Artificial Intelligence Thought Leaders and the Launch of PsyAI™
MagicMed Industries announces an R&D partnership for the development of PsyAI(TM), a an AI-based tool to "modernize psychedelic medicine."
Other Psychedelic Stocks Get Cheaper As atai Gets More Expensive
If atai Life Sciences trades in the expected manner off its IPO, its market cap will quickly exceed the COMBINED market caps of all other psychedelic stocks.
MINDCURE (CSE: MCUR | OTCQB: MCURF) Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research
The Company expects to have ibogaine manufactured and in use for research by Q4.
atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round
ATAI announces closing its Series D financing round, raising $157 million.
Iowa Lawmakers Hold Historic Hearing On Psilocybin Decriminalization, But Do Not Advance Bill
In a first-of-its kind hearing, an Iowa House panel on Wednesday took up a bill to decriminalize psilocybin mushrooms in the state.
Biggest Opportunities for Psychedelic Drugs OUTSIDE of Mental Health?
The Mental Health Crisis is a huge opportunity for psychedelic drugs. But the BIGGEST potential markets may exist outside of mental health.
MINDCURE (CSE: MCUR | OTCQB MCURF) Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
The completed equity investment strengthens ties between MINDCURE and ATMA